VERTEX PHARMACEUTICALS INC / MA Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options (Deprecated 2017-01-31)
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options (Deprecated 2017-01-31) of $48.50 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-23.
Discontinued › Notes › Compensation Related Costs
us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions · last filed 2017-02-23
- VERTEX PHARMACEUTICALS INC / MA employee service share-based compensation, cash received from exercise of stock options (deprecated 2017-01-31) for fiscal 2016 was $48.50M, a 70.71% decline from fiscal 2015.
- VERTEX PHARMACEUTICALS INC / MA employee service share-based compensation, cash received from exercise of stock options (deprecated 2017-01-31) for fiscal 2015 was $165.60M, a 35.19% decline from fiscal 2014.
- VERTEX PHARMACEUTICALS INC / MA employee service share-based compensation, cash received from exercise of stock options (deprecated 2017-01-31) for fiscal 2014 was $255.50M, a 3.53% increase from fiscal 2013.
- VERTEX PHARMACEUTICALS INC / MA employee service share-based compensation, cash received from exercise of stock options (deprecated 2017-01-31) for fiscal 2013 was $246.80M, a 42.82% increase from fiscal 2012.
| Period end | Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options (Deprecated 2017-01-31) 12 month |
|---|---|
| 2016-12-31 | $48.50M 10-K · filed 2017-02-23 |
| 2015-12-31 | $165.60M 10-K · filed 2017-02-23 |
| 2014-12-31 | $255.50M 10-K · filed 2017-02-23 |
| 2013-12-31 | $246.80M 10-K · filed 2016-02-16 |
| 2012-12-31 | $172.80M 10-K · filed 2015-02-13 |
| 2011-12-31 | $109.60M 10-K · filed 2014-02-11 |
| 2010-12-31 | $22.20M 10-K · filed 2013-03-01 |
| 2009-12-31 | $38.20M 10-K · filed 2012-02-22 |
| 2008-12-31 | $24.10M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |